Publications by authors named "H Erdal Ozkan"
Article Synopsis
- The study focuses on using waste frying oil as a carbon source to produce cost-effective rhamnolipids, overcoming common production barriers.
- Optimal conditions for rhamnolipid production were identified, resulting in a yield of 2.97 g/l at specific temperature, pH, and incubation time.
- The research indicates that using Halopseudomonas sabulinigri OZK5 for biosurfactant production is a promising biotechnological approach due to its eco-friendliness and efficiency.
This study investigated expressions of microRNA (miR)-26a, miR-27a, and miR-148a in plasma, colostrum and milk collected on different days (0th, 4th, 7th, 14th, and 28th days) during transition from colostrum to milk in Awassi sheep. Relationships between miRNAs and quality parameters were also explored. During transition, Somatic Cell Count, Fat-free dry matter, protein, lactose decreased, pH, freezing point (FP), electrical conductivity (EC) increased.
View Article and Find Full Text PDFArticle Synopsis
- This study explores the outcomes and management of pediatric auditory brainstem implantation (ABI) for children with severe inner ear malformations, aiming to unify clinical practices and address current challenges.
- A systematic review of relevant findings from the Third International Pediatric ABI Symposium analyzed data from multiple countries, highlighting trends in auditory outcomes, surgical approaches, and rehabilitation strategies.
- Key conclusions emphasize the need for standardized guidelines and improved collaboration among healthcare professionals to enhance patient outcomes and guide future research in this specialized field.
Objective: In this study, we aimed to obtain real-life data on the use of antimyeloma agents, which significantly increase overall survival (OS) in multiple myeloma (MM) patients, in primary plasma cell leukemia (pPCL) patients with poor prognosis.
Materials And Methods: Data from 53 patients who were diagnosed with pPCL between 2011 and 2020 and who used at least one proteasome inhibitor (PI) and/or immunomodulatory (IMID) agent were analyzed retrospectively. Depending on the year of the pPCL diagnosis, 20% leukocytes or ≥2x10/L plasma cells in the peripheral blood was used as a diagnostic criterion.
Background: Adverse non-motor outcomes have a major impact on patients and caregivers after stroke, but knowledge of their prevalence, predictors and patterns across multiple health domains remains limited; we therefore aimed to obtain these data in a large observational prospective cohort study.
Methods: We included data from the Stroke Investigation Group in North and Central London (SIGNAL) registry based at the University College London Hospitals (UCLH) Comprehensive Stroke Service which serves a multi-ethnic population of ∼1.6 million people.